Compare TMC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | HRMY |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2020 | 2020 |
| Metric | TMC | HRMY |
|---|---|---|
| Price | $4.29 | $41.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $8.85 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 6.9M | 636.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | 7.97 |
| EPS | 0.19 | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | N/A | $12.88 |
| P/E Ratio | $23.47 | ★ $22.86 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $3.40 | $25.52 |
| 52 Week High | $11.35 | $43.49 |
| Indicator | TMC | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 61.17 |
| Support Level | $4.24 | $37.30 |
| Resistance Level | $4.81 | N/A |
| Average True Range (ATR) | 0.32 | 1.29 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 34.57 | 66.89 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.